Treatment Satisfaction With Ra-223 in Japan

Status Completed

Clinical Trial Summary

This study aims to answer the research question: Are Japanese bone metastatic CRPC patients satisfied with their Ra-223 treatment, and what factors drive such satisfaction? It also aims to determine patient anxiety regarding prostate cancer while on treatment with Ra-223, and assess the effect on quality of life.

Clinical Trial Description

This is a local, Japanese, prospective, longitudinal, observational, company-sponsored, multi-center, single arm study that will describe treatment satisfaction with Ra-223 in 150 bone metastatic CRPC patients on 1st to 3rd line CRPC therapy. All outcomes will be obtained using PRO questionnaires at 4 time points: before treatment, during treatment, and at 1-month after the last treatment cycle. ;

Study Design

Related Conditions & MeSH terms

Prostatic Neoplasms

Clinical Trial Details

NCT number	NCT03315260
Study type	Observational
Source	Bayer
Contact
Status	Completed
Phase
Start date	April 11, 2019
Completion date	March 20, 2023

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04964271` - Identification of Prostate Cancer Specific Markers in Patients Compared to Healthy Participants
Completed	`NCT02546908` - A Registry of Participants With Prostate Cancer in Asia
Completed	`NCT04838626` - Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection	Phase 2/Phase 3
Recruiting	`NCT03101176` - Multiparametric Ultrasound Imaging in Prostate Cancer	N/A
Completed	`NCT01683994` - Cabozantinib Plus Docetaxel and Prednisone for Advanced Prostate Cancer	Phase 1/Phase 2
Completed	`NCT04838613` - Study of Diagnostic Performance of [18F]CTT1057 in BCR	Phase 3
Completed	`NCT02364531` - A Canadian Observational Study in Metastatic Cancer of the Prostate: A Study of ZYTIGA Use in the Community Urology Setting
Completed	`NCT01929655` - Japanese BAY88-8223 Monotherapy Phase II Study	Phase 2
Active, not recruiting	`NCT05022849` - A Study of JNJ-75229414 for Metastatic Castration-resistant Prostate Cancer Participants	Phase 1
Completed	`NCT03261999` - Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate (LMIS 25 mg) in Subjects With Prostate Cancer	Phase 3
Terminated	`NCT04907227` - Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921)-China Extension	Phase 3
Active, not recruiting	`NCT03587285` - A Pilot Study of Hormonal Therapy Combined With Central Memory T Cells (Tcm) for Patients With Advanced Prostate Cancer	Phase 1/Phase 2
Completed	`NCT02217566` - Study of Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC), Chemo-Naive, Who Received a Prior Diethylstilbestrol Therapy	Phase 2
Not yet recruiting	`NCT04101305` - Measurement of Circulating Tumor Cells in Prostate Cancer
Recruiting	`NCT03066154` - Oral Docetaxel (ModraDoc/r) in Combination With Hormonal Treatment and Radiation Therapy in High-risk Prostate Cancer	Phase 1
Active, not recruiting	`NCT02950064` - A Study to Determine the Safety of BTP-114 for Treatment in Patients With Advanced Solid Tumors With BRCA Mutations	Phase 1
Withdrawn	`NCT02905201` - A Prospective Compliance Registry for Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)	N/A
Completed	`NCT02692976` - Natural Dendritic Cells for Immunotherapy of Chemo-naive Metastatic Castration-resistant Prostate Cancer Patients	Phase 2
Terminated	`NCT01420965` - Sipuleucel-T, CT-011, and Cyclophosphamide for Advanced Prostate Cancer	Phase 2
Completed	`NCT01441713` - Treatment Frequency and Satisfaction in Patients With Advanced Prostate Cancer	N/A